JDRF response to UK Government’s reassurances on insulin supplies during European Union exit
Posted on 31 July 2018
The type 1 diabetes charity JDRF has commented on the issue of the UK’s supplies of insulin during its exit from the European Union.
The Chair of the UK’s medicines regulator said on 27th July that insulin supply chains in the event of the UK leaving the EU without a deal have “got to be sorted”. Sir Michael Rawlins, Chair of the Medicines and Healthcare products Regulatory Agency (MHRA), highlighted that as a nation, “we import every drop” of insulin for people with diabetes.
But the UK Government’s Health Secretary, Matt Hancock, then stated in Parliament that thorough contingency plans were being made. He said: “Any responsible Government need to prepare for a range of outcomes, including the unlikely scenario of no deal… We are working right across Government to ensure that the health sector and the industry are prepared, and that people’s health will be safeguarded in the event of a no-deal Brexit.
“This includes the chain of medical supplies, as you mention, vaccines, medical devices, clinical consumables and blood products. I have asked the Department to work up options for stockpiling by industry, and we are working with industry to prepare for the potential need for stockpiling in the event of a no-deal Brexit. This is exactly the type of contingency planning that you would expect us to be doing.”
Insulin manufacturers have told the UK media that they do not expect significant disruption to supplies of insulin to the UK, even in the event of a ‘no deal’ end to the UK’s membership of the European Union.
Michael Connellan, UK Head of External Affairs at the type 1 diabetes charity JDRF, said in response: “JDRF will be writing to the UK Government’s Department for Exiting the European Union and the Department of Health and Social Care. We will be asking, on behalf of the 400,000 UK people living with type 1 diabetes, to be kept well informed of developments in plans to ensure medical supply chains for type 1 diabetes are completely unaffected.”
Want more news like this?
Sign up to our e-newsletter and get articles like this directly into your inboxSign up here